Induction of NK cell reactivity against acute myeloid leukemia by Fc-optimized CD276 (B7-H3) antibody., PMID:38637557
B7-H3-Targeting Chimeric Antigen Receptors Epstein-Barr Virus-specific T Cells Provides a Tumor Agnostic Off-The-Shelf Therapy Against B7-H3-positive Solid Tumors., PMID:38717140
CD276 regulates the immune escape of esophageal squamous cell carcinoma through CXCL1-CXCR2 induced NETs., PMID:38724465
The bispecific B7H3xCD3 antibody CC-3 induces T cell immunity against bone and soft tissue sarcomas., PMID:38765008
Chimeric Antigen Receptor T Cell with an Inducible Caspase-9 Suicide Gene Eradicates Uveal Melanoma Liver Metastases via B7-H3 Targeting., PMID:38767611
Targeting both GD2 and B7-H3 using bispecific antibody improves tumor selectivity for GD2-positive tumors., PMID:38853889
Development of DNA aptamers targeting B7H3 by hybrid-SELEX: an alternative to antibodies for immuno-assays., PMID:38866941
Differential Immune Checkpoint Protein Expression in HNSCC: The Role of HGF/MET Signaling., PMID:39000441
Expression and Prognostic Value of a Novel B7-H3 (CD276) Antibody in Acute Myeloid Leukemia., PMID:39001517
CAR T-cells targeting FGFR4 and CD276 simultaneously show potent antitumor effect against childhood rhabdomyosarcoma., PMID:39043633
Diet restriction enhances the effect of immune checkpoint block by inhibiting the intratumoral mTORC1/B7-H3 axis., PMID:39132973
ITGB6 modulates resistance to anti-CD276 therapy in head and neck cancer by promoting PF4+ macrophage infiltration., PMID:39152118
A Dual-Payload Antibody-Drug Conjugate Targeting CD276/B7-H3 Elicits Cytotoxicity and Immune Activation in Triple-Negative Breast Cancer., PMID:39186778
B7 homolog 3 in pancreatic cancer., PMID:39193002
Genetically engineered CD276-anchoring biomimetic nanovesicles target senescent escaped tumor cells to overcome chemoresistant and immunosuppressive breast cancer., PMID:39226654
Multiplexed Spatial Imaging at the Single-Cell Level Reveals Mutually Exclusive Expression of B7 Family Proteins., PMID:39244158
B7-H3 promotes nasopharyngeal carcinoma progression by regulating CD8+ T cell exhaustion., PMID:39267471
A B7-H3-Targeted CD28 Bispecific Antibody Enhances the Activity of Anti-PD-1 and CD3 T-cell Engager Immunotherapies., PMID:39301613
Development of a Specifically Labeled 89Zr Antibody for the Noninvasive Imaging of Tumors Overexpressing B7-H3., PMID:39322604
Novel bispecific antibody-drug conjugate targeting PD-L1 and B7-H3 enhances antitumor efficacy and promotes immune-mediated antitumor responses., PMID:39357981
Targeting CD276 for T cell-based immunotherapy of breast cancer., PMID:39367484
Targeting overexpressed antigens in glioblastoma via CAR T cells with computationally designed high-affinity protein binders., PMID:39420062
Ultrasound Molecular Imaging Enhances High-Intensity Focused Ultrasound Ablation on Liver Cancer With B7-H3-Targeted Microbubbles., PMID:39431644
Preclinical evaluation of antigen-sensitive B7-H3-targeting nanobody-based CAR-T cells in glioblastoma cautions for on-target, off-tumor toxicity., PMID:39562005
Prognostic value of B7-H3 expression in metastatic renal cell carcinoma and its impact on immunotherapy response., PMID:39614178
Engineered oncolytic virus expressing B7H3-targeting BiTE enhances antitumor T-cell immune response., PMID:39615894
B7-H3 in glioblastoma and beyond: significance and therapeutic strategies., PMID:39664380
Assessment of targets of antibody drug conjugates in SCLC., PMID:39748112
Statins inhibit onco-dimerization of the 4Ig isoform of B7-H3., PMID:39763965
The inhibitory effects of nimotuzumab on CD276 expression and immune escape in head and neck squamous cell carcinoma: Insights into anticancer mechanisms., PMID:39778280
PRMT5-Mediated ALKBH5 Methylation Promotes Colorectal Cancer Immune Evasion via Increasing CD276 Expression., PMID:39781264
Engineered T cells secreting αB7-H3-αCD3 bispecific engagers for enhanced anti-tumor activity against B7-H3 positive multiple myeloma: a novel therapeutic approach., PMID:39806405
Unraveling the dynamics of B7-H3-targeting therapeutic antibodies in cancer through PET imaging and antibody pharmacokinetics., PMID:39814321
An immunohistochemical and molecular genetic study of 60 colorectal carcinoma brain metastases in pursuit of predictive biomarkers for cancer therapy., PMID:39824298
Lineage-dependence of the neuroblastoma surfaceome defines tumor cell state-dependent and independent immunotherapeutic targets., PMID:39825754
A humanized anti-b7h3×4-1BB bispecific antibody exerts potent antitumour effects through the activation of innate and adaptive immunity., PMID:39847994
Identification and characterization of CD83 and CD276 as markers of dendritic cells in olive flounder (Paralichthys olivaceus)., PMID:39848419
Novel B7-H3 CAR T cells show potent antitumor effects in glioblastoma: a preclinical study., PMID:39863300
B7-H3-liquid biopsy for the characterization and monitoring of the dynamic biology of prostate cancer., PMID:39914189
The AURKA inhibitor alters the immune microenvironment and enhances targeting B7-H3 immunotherapy in glioblastoma., PMID:39928563
Advances in adoptive cell therapies in small cell lung cancer., PMID:40160238
Molecular Imaging of B7-H3-Targeting Bispecific T Cell-Engaging Antibody MGD009 in Glioblastoma Models., PMID:40183579
B7H3 in Gastrointestinal Tumors: Role in Immune Modulation and Cancer Progression: A Review of the Literature., PMID:40214484
Codelivery of apigenin, FdUMP and CD276 antibody synergistic inhibit colorectal cancer by ferroptosis-apoptosis-pyroptosis and CD276 blockade., PMID:40224726
Targeting site-specific N-glycosylated B7H3 induces potent antitumor immunity., PMID:40229277
Biomarkers of response to antibody-drug conjugates (TROP2 and nectin-4) and the immune microenvironment (NKG7, PD-L1, and B7-H3) in penile squamous cell carcinoma., PMID:40327767
Actionable heterogeneity of hepatocellular carcinoma therapy-induced senescence., PMID:40374812
m276-SL-PBD eradicates tumors and instigates long-lasting tumor-free survival in Merkel cell carcinoma preclinical models., PMID:40384933
PARP inhibitors accumulate B7-H3 on fibroblasts via blocking autophagic flux to potentiate immune evasion in ovarian cancer., PMID:40497528
Utilization of universal-targeting mSA2 CAR-T cells for the treatment of glioblastoma., PMID:40518621
For research use only. Not for human or drug use.
